Inhaled steroids to be tested as a possible treatment for COVID-19 as part of PRINCIPLE trial | NIHR
RACGP - Why are asthma patients not at increased susceptibility to COVID?
Will BA.2.86 ('Pirola'), the New Coronavirus Variant, Increase COVID-19 Cases? > News > Yale Medicine
My Teacher's Mask: Back To School During Covid-19: Puffer, Inga: 9798672844480: Amazon.com: Books
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective | European Respiratory Society
Asthma Treatments for COVID-19 - Asthma Australia
Second study confirms benefits of budesonide in early stages of COVID-19 | NIHR Oxford Biomedical Research Centre
Study Finds No Benefit to Taking Fluticasone Furoate for COVID-19 Symptoms | Duke Health
Media kit on COVID-19
Inhaled asthma drug shortens Covid recovery and could be 'significant for world,' study finds | The Independent
These COVID-19 patients survived. But they never recovered - WHYY
Inhaled corticosteroids: not just for asthma, but for COVID-19? - The Lancet Respiratory Medicine
Covid: Asthma drug 'speeds up recovery at home' - BBC News
Critical inhaler medication shortage looms as coronavirus cases soar - ABC News
Montreal researchers testing potential COVID-19 treatment with steroid inhaler | CTV News
COVID 19 and asthma Our expert answers your questions | VCU Health
A message to asthma sufferers about a shortage of albuterol metered dose inhalers - ACAAI Public Website
Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey | BMJ Open Respiratory Research
How Puffer-Sweiven is Responding to COVID-19
Asthma inhalers being trialed for treatment of COVID-19
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19 | University of Oxford
Asthma drug may reduce risk of severe Covid if taken early – study | Coronavirus | The Guardian
COVID-19 causing inhaler shortage for asthmatics: experts | Miami Herald
Inhaled Steroid Disappoints for COVID-19 | MedPage Today
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial - The Lancet
